

Atty Dkt No. 0366.103 USSN: 09/509,612 PATENT

## **CURRENTLY PENDING CLAIMS**

- 7. (Amended) A method for treating an infection of HCV comprising administering to a patient a therapeutically effective amount of a CD81 protein, or a functional equivalent thereof, to reduce the infectivity of the virus.
- 27. (New) The method of claim 7, wherein the functional equivalent has at least 80% sequence identity to the human CD81 amino acid sequence depicted in Figure 1.
- 28. (New) The method of claim 7, wherein the functional equivalent is a soluble form of the CD81 protein.
- 29. (New) The method of claim 28, wherein the soluble form of the CD81 protein comprises a deletion of one or more of the transmembrane binding domains depicted as TM1, TM2, TM3 and TM4 in Figure 1.
- 30. (New) The method of claim 29, wherein the soluble form of the CD81 protein comprises amino acids 113-201 of the human CD81 amino acid sequence depicted in Figure 1.
- 31. (New) The method of claim 7, wherein the CD81 protein comprises the human CD81 amino acid sequence depicted in Figure 1.